Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan

References

• The World Health Organization. (2000) The leishmaniases and leishmania/HIV co-infections. Geneva: WHO Fact Sheet.
   Google Scholar
• Costa CH. (2008). Characterization and speculations on the urbanization of visceral leishmaniasis in Brazil. Cad Saude Publica, 24:2959–63.
   PubMed Web of Science ®Google Scholar
• Hassan MM, Osman OF, El-Raba’a FM, Schallig HD, Elnaiem DE. (2009). Role of the domestic dog as a reservoir host of Leishmania donovani in eastern Sudan. Parasit Vectors, 2:26.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chatterjee M. (2006). Visceral leishmaniasis—current therapeutic modalities. Indian J Med Res, 123:345–52.
   PubMed Web of Science ®Google Scholar
• Moore E, O’Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, . (2001). Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ, 79:388–93.
   PubMed Web of Science ®Google Scholar
• Veeken H, Ritmeijer K, Seaman J, Davidson R. (2000). A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health, 5:312–7.
   PubMed Web of Science ®Google Scholar
• Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, . (2003). Treatment of visceral leishmaniasis in south-eastern Nepal: Decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg, 97:350–4.
   PubMed Web of Science ®Google Scholar
• Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, . (2008). Drug regimens for visceral leishmaniasis in mediterranean countries. Trop Med Int Health, 13:1272–6.
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. (2005). Treatment of visceral leishmaniasis. Expert Opin Pharmacother, 6(16):2821–29.
   PubMed Web of Science ®Google Scholar
• Croft SL, Sundar S, Fairlamb AH. (2006). Drug resistance in leishmaniasis. Clin Microbiol Rev, 19:111–26.
   PubMed Web of Science ®Google Scholar
• Davidson RN, den Boer M, Ritmeijer K. (2009). Paromomycin. Trans R Soc Trop Med Hyg, 103:653–60.
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. (2009). Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin Infect Dis, 49:914–8.
   PubMed Web of Science ®Google Scholar
• Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. (2005). Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis, 5:763–74.
   PubMed Web of Science ®Google Scholar
• Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. (2004). Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations. Clin Infect Dis, 38:377–83.
   PubMed Web of Science ®Google Scholar
• Olliaro P, Sundar S. (2009). Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health, 14:88–92.
   PubMed Web of Science ®Google Scholar
• Sundar S, Murray HW. (2005). Availability of miltefosine for the treatment of Kala-azar in India. Bull World Health Organ, 83:394–5.
   PubMed Web of Science ®Google Scholar
• Meheus F, Boelaert M, Baltussen R, Sundar S. (2006). Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health, 11:1715–24.
   PubMed Web of Science ®Google Scholar
• Bern C, Chowdhury R. (2006). The epidemiology of visceral leishmaniasis in Bangladesh: Prospects for improved control. Indian J Med Res, 123:275–88.
   PubMed Web of Science ®Google Scholar
• Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, . (2003). Visceral leishmaniasis: Consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg, 69:624–8.
   PubMed Web of Science ®Google Scholar
• Sharma AD, Bern C, Varghese B, Chowdhury R, Haque R, Ali M, . (2006). The economic impact of visceral leishmaniasis on households in Bangladesh. Trop Med Int Health, 11:757–64.
   PubMed Web of Science ®Google Scholar
• Luz ZM, Carneiro M, Schall V, Rabello A. (2009). The organization of health services and visceral leishmaniasis: An integrated intervention to improve diagnosis and treatment. Cad Saude Publica, 25:1177–84.
   PubMedGoogle Scholar
• Dantas-Torres F, Brandao-Filho SP. (2006). Visceral leishmaniasis in Brazil: Revisiting paradigms of epidemiology and control. Rev Inst Med Trop Sao Paulo, 48:151–6.
   PubMedGoogle Scholar
• Brasil Ministerio da Saude.(2005). Secretaria de Vigilancia em Saude. Guia de vigilancia epidemiologica/Ministerio da Saude, Secretaria de Vigilancia em Saude. 6th ed. Brasilia: Ministerio da Saude, 816 p. Serie A. Normas e Manuais Tecnicos.
   Google Scholar
• Amato, VS, Tuon, FF, Siqueira AM, Nicodemo AC, Neto VA. (2007). Treatment of mucosal leishmaniasis in Latin America: A systematic review. Am J Trop Med Hyg, 77(2):266–74.
   PubMed Web of Science ®Google Scholar
• Dietze R, Barros GB, Teixeira L, Harris J, Michelson K, Falqueto A, . (1997). Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Infect Dis, 25:1240–2.
   PubMed Web of Science ®Google Scholar
• Hotez PJ. (2008). The giant anteater in the room: Brazil’s neglected tropical diseases problem. PLoS Negl Trop Dis, 2:e177.
   PubMedGoogle Scholar
• The World Bank. (2004). Inequality and economic development in Brazil, a World Bank country study. Washington: The International Bank for Reconstruction and Development, XVIII.
   Google Scholar
• Schenkel K, Rijal S, Koirala S, Koirala S, Vanlerberghe V, Van der Stuyft P, . (2006). Visceral leishmaniasis in southeastern Nepal: A cross-sectional survey on leishmania donovani infection and its risk factors. Trop Med Int Health, 11:1792–9.
   PubMed Web of Science ®Google Scholar
• Adhikari SR, Maskay NM. (2003). The economic burden of Kala-azar in households of the Danusha and Mahottari districts of Nepal. Acta Trop, 88:1–2.
   PubMed Web of Science ®Google Scholar
• Adhikari SR, Maskay NM, Sharma BP. (2009). Paying for hospital-based care of Kala-azar in Nepal: Assessing catastrophic, impoverishment and economic consequences. Health Policy Plan, 24:129–39.
   PubMed Web of Science ®Google Scholar
• Rijal S, Koirala S, Van der Stuyft P, Boelaert M. (2006). The economic burden of visceral leishmaniasis for households in Nepal. Trans R Soc Trop Med Hyg, 100(9):838–41.
   PubMed Web of Science ®Google Scholar
• Kolaczinski JH, Hope A, Ruiz JA, Rumunu J, Richer M, Seaman J. (2008). Kala-azar epidemiology and control, Southern Sudan. Emerg Infect Dis, 14:664–6.
   PubMed Web of Science ®Google Scholar
• Griekspoor A, Sondorp E, Vos T. (1999). Cost-effectiveness analysis of humanitarian relief interventions: Visceral leishmaniasis treatment in the Sudan. Health Policy Plan, 14:70–6.
   PubMed Web of Science ®Google Scholar
• Gerstl S, Amsalu R, Ritmeijer K. (2006). Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan. Trop Med Int Health, 11:167–75.
   PubMed Web of Science ®Google Scholar
• Alvar J, Yactayo S, Bern C. (2006). Leishmaniasis and poverty. Trends Parasitol, 22:552–7.
   PubMed Web of Science ®Google Scholar
• Thakur BB. (2003). Breakthrough in the management of visceral leishmaniasis. J Assoc Physicians India, 51:649–51.
   PubMedGoogle Scholar
• Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, . (2007). Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis, 196:591–8.
   PubMed Web of Science ®Google Scholar
• Palumbo E. (2008). Oral miltefosine treatment in children with visceral leishmaniasis: A brief review. Braz J Infect Dis, 12:2–4.
   PubMed Web of Science ®Google Scholar
• Berman JJ. (2008). Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin Drug Metab Toxicol, 4:1209–16.
   PubMed Web of Science ®Google Scholar
• Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, . (2009). Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis, 200:357–60.
   PubMed Web of Science ®Google Scholar
• Thornton SJ, Wasan KM. (2009). The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv, 6:271–84.
   PubMed Web of Science ®Google Scholar